Sapience Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

TARRYTOWN, N.Y., April 3, 2024 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today announced its participation at the 23^rd Annual Needham Virtual Healthcare Conference, being held April 8-11, 2024. 

Sapience CEO and President, Dr. Barry Kappel, will present a company overview on Monday, April 8, 2024, at 1:30 pm ET. Company management will also participate in virtual one-on-one meetings with investors during the conference.

About Sapience Therapeutics

Sapience Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing peptide therapeutics to address oncogenic and immune dysregulation that drive cancer.  With in-house discovery capabilities, Sapience has built a pipeline of therapeutic candidates called SPEARstm (Stabilized Peptides Engineered Against Regulation) that disrupt intracellular protein-protein interactions, enabling targeting of transcription factors which have traditionally been considered undruggable. Sapience is advancing its lead programs, ST316, a first-in-class antagonist of ?-catenin, and ST101, a first-in-class antagonist of C/EBP?, through Phase 1-2 clinical trials. 

For more information on Sapience Therapeutics, please visit www.sapiencetherapeutics.com and engage with us on LinkedIn.

Media and Investor Contact:
Amy Conrad
Juniper Point
(858) 366-3243
[email protected]

SOURCE Sapience Therapeutics, Inc.